Anne Wojcicki buys 23andme and his data for $ 305 million,
23Andme founder Anne Wojcicki speaks on June 10, 2025 during a reform committee for supervision and reform of the government in Washington, DC.
Andrew Harnik | Getty pictures
Anne Wojcicki, the co-founder and former CEO of 23Andme, has regained control of the competitive genetic test company according to her new non-profit TTAM Research Institute Outbid Regeneron pharmaceuticalsThe company announced Friday.
TTAM will essentially acquire all assets of 23Ande for $ 305 million, including the business limits for personal genome service and research services as well as the subsidiary of telemedicine subsidiary Lemonaid. It is a great victory for Wojcicki, who resigned from her role as CEO when 23Andme submitted insolvency protection in Chapter 11 in March.
Last month, Regeneron announced that it would purchase most of the 23 -amm assets for $ 256 million after it was ahead during an insolvency auction. But Wojcicki submitted a separate offer of 305 million US dollars via TTAM and urged to reopen the auction. According to Wall Street Journal, TTAM is an abbreviation for the first letters from 23Andme.
“I am thrilled that the TTAM research institute can continue the 23Andme mission to help people access, understand and benefit from human genome,” said Wojcicki in an explanation.
Due to his DNA test kits, 23Andme gained popularity at home, which gave customers an insight into their family history and genetic profiles. In 2021, the five -time CNBC Disruptor 50 Company went to the stock exchange with a merger with a special company for purposes. At its climax, 23Andme had a value of around 6 billion US dollars.
The company tried to generate recurring earnings and to face the public for viable research and therapists, and it was plagued by data protection concerns, since Hacker accessed the information from almost 7 million customers in 2023.
The acquisition of TTAM is still subject to the approval of the US insolvency court for the eastern district of Missouri.
Do not miss these findings from CNBC Pro
